After the Revolution? Ethical and Social Challenges in 'personalized Genomic Medicine'

Overview

Journal Per Med

Specialties General Medicine
Genetics

Date 2013 May 11

PMID 23662108

Citations 19

Authors

Eric T Juengst

Richard A Settersten Jr

Jennifer R Fishman

Michelle L McGowan

Affiliations

Soon will be listed here.

Abstract

Personalized genomic medicine (PGM) is a goal that currently unites a wide array of biomedical initiatives, and is promoted as a 'new paradigm for healthcare' by its champions. Its promissory virtues include individualized diagnosis and risk prediction, more effective prevention and health promotion, and patient empowerment. Beyond overcoming scientific and technological hurdles to realizing PGM, proponents may interpret and rank these promises differently, which carries ethical and social implications for the realization of PGM as an approach to healthcare. We examine competing visions of PGM's virtues and the directions in which they could take the field, in order to anticipate policy choices that may lie ahead for researchers, healthcare providers and the public.

Citing Articles

Inadvertent human genomic bycatch and intentional capture raise beneficial applications and ethical concerns with environmental DNA.

Whitmore L, McCauley M, Farrell J, Stammnitz M, Koda S, Mashkour N Nat Ecol Evol. 2023; 7(6):873-888.

PMID: 37188965 PMC: 10250199. DOI: 10.1038/s41559-023-02056-2.

Investigating acceptability of a training programme in precision medicine for frontline healthcare professionals: a mixed methods study.

Mitchell S, Jaccard E, Schmitz F, von Kanel E, Collombet P, Cornuz J BMC Med Educ. 2022; 22(1):556.

PMID: 35850770 PMC: 9294840. DOI: 10.1186/s12909-022-03613-2.

Adapting a conceptual framework to engage diverse stakeholders in genomic/precision medicine research.

Watson K, Cohn E, Fair A, Menon U, Szalacha L, Carpenter S Health Expect. 2022; 25(4):1478-1485.

PMID: 35353945 PMC: 9327871. DOI: 10.1111/hex.13486.

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes.

Bizzarri M, Fedeli V, Monti N, Cucina A, Jalouli M, Alwasel S EPMA J. 2021; 12(4):545-558.

PMID: 34642594 PMC: 8495186. DOI: 10.1007/s13167-021-00254-1.

Governing Personalized Health: A Scoping Review.

Trein P, Wagner J Front Genet. 2021; 12:650504.

PMID: 33968134 PMC: 8097042. DOI: 10.3389/fgene.2021.650504.

References

Guttmacher A, Collins F, Carmona R . The family history--more important than ever. N Engl J Med. 2004; 351(22):2333-6. DOI: 10.1056/NEJMsb042979. View

Whitehouse P, Juengst E . Antiaging medicine and mild cognitive impairment: practice and policy issues for geriatrics. J Am Geriatr Soc. 2005; 53(8):1417-22. DOI: 10.1111/j.1532-5415.2005.53411.x. View

Post S . Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophr Res. 2001; 51(1):103-8. DOI: 10.1016/s0920-9964(01)00246-8. View

Powell K, Christianson C, Cogswell W, Dave G, Verma A, Eubanks S . Educational needs of primary care physicians regarding direct-to-consumer genetic testing. J Genet Couns. 2011; 21(3):469-78. DOI: 10.1007/s10897-011-9471-9. View

Taylor P . Personal genomes: when consent gets in the way. Nature. 2008; 456(7218):32-3. DOI: 10.1038/456032a. View

McGowan M, Fishman J . Using lessons learned from BRCA testing and marketing: what lies ahead for whole genome scanning services. Am J Bioeth. 2008; 8(6):18-20. PMC: 3806448. DOI: 10.1080/15265160802248302. View

Rothstein M, Epps P . Ethical and legal implications of pharmacogenomics. Nat Rev Genet. 2001; 2(3):228-31. DOI: 10.1038/35056075. View

Offit K . Genomic profiles for disease risk: predictive or premature?. JAMA. 2008; 299(11):1353-5. DOI: 10.1001/jama.299.11.1353. View

Maienschein J, Sunderland M, Ankeny R, Robert J . The ethos and ethics of translational research. Am J Bioeth. 2008; 8(3):43-51. DOI: 10.1080/15265160802109314. View

10.

Zerhouni E . Medicine. The NIH Roadmap. Science. 2003; 302(5642):63-72. DOI: 10.1126/science.1091867. View

11.

Janssens A, Gwinn M, Bradley L, Oostra B, Van Duijn C, Khoury M . A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008; 82(3):593-9. PMC: 2427295. DOI: 10.1016/j.ajhg.2007.12.020. View

12.

Hudson K . The health benefits of genomics: out with the old, in with the new. Health Aff (Millwood). 2008; 27(6):1612-5. DOI: 10.1377/hlthaff.27.6.1612. View

13.

Trusheim M, Berndt E, Douglas F . Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007; 6(4):287-93. DOI: 10.1038/nrd2251. View

14.

Obama B . The genomics and Personalized Medicine Act of 2006. Clin Adv Hematol Oncol. 2007; 5(1):39-40. View

15.

Burke W, Kuszler P, Starks H, Holland S, Press N . Translational genomics: seeking a shared vision of benefit. Am J Bioeth. 2008; 8(3):54-6. PMC: 2633471. DOI: 10.1080/15265160802109488. View

16.

Lee S, Crawley L . Research 2.0: social networking and direct-to-consumer (DTC) genomics. Am J Bioeth. 2009; 9(6-7):35-44. DOI: 10.1080/15265160902874452. View

17.

Ioannidis J . Expectations, validity, and reality in omics. J Clin Epidemiol. 2010; 63(9):945-9. DOI: 10.1016/j.jclinepi.2010.04.002. View

18.

Rhodes R . Rethinking research ethics. Am J Bioeth. 2005; 5(1):7-28. DOI: 10.1080/15265160590900678. View

19.

Harmon A . Couples cull embryos to halt heritage of cancer. N Y Times Web. 2007; :A1, A20. View

20.

Kahn J . Race, pharmacogenomics, and marketing: putting BiDil in context. Am J Bioeth. 2006; 6(5):W1-5. DOI: 10.1080/15265160600755789. View